Form 4: Stryker COO Granted Stock Options

Stryker's President and COO, Spencer S. Stiles, was granted 19,956 employee stock options with an exercise price of $360.82.

Summary

• Spencer S. Stiles, President and COO of Stryker Corp (SYK), was granted 19,956 employee stock options.
• The options were granted on February 4, 2026, with an exercise price of $360.82 per share.
• These options become exercisable as to 20% on each of the first five anniversaries of the grant date.
• The options expire on February 3, 2036.
• The grant was made pursuant to the Stryker Corporation 2011 Long-Term Incentive Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at aligning management incentives with shareholder interests, without indicating any significant operational or financial changes.

Positives

• The grant of stock options aligns the interests of President and COO Spencer S. Stiles with those of shareholders, incentivizing long-term performance and value creation.

Negatives

• The future exercise of these options could lead to a minor dilutive effect on existing shares, although this is a standard component of executive compensation plans.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction, focusing solely on an executive compensation transaction.

Industry Context

StockSavvy.ai notes that the grant of stock options to key executives like a President and COO is a common practice in the medical technology and broader corporate sectors. Such grants are designed to align executive incentives with shareholder value creation over the long term, a standard approach to executive compensation across industries.

Comparison to Industry Standards

• The structure of this option grant, with a five-year vesting schedule (20% annually), is consistent with typical long-term incentive plans observed in large-cap medical device companies such as Medtronic (MDT) or Johnson & Johnson (JNJ), which often use multi-year vesting to encourage sustained performance.
• The exercise price being set at the market price on the grant date is standard for non-qualified stock options, ensuring that the executive benefits only if the stock price appreciates from the grant date.

Stakeholder Impact

• Shareholders: Potential for enhanced management alignment with long-term company performance; minor future dilution upon option exercise.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• The options will vest at 20% annually over the next five years, starting from February 4, 2027.

Key Dates

Keywords

Stryker, SYK, Stock Options, Executive Compensation, Insider Transaction, Form 4, Spencer S. Stiles, Long-Term Incentive Plan